“Pursuit of medium-term fiscal balance”

(Boursier.com) — 2021, Safe group Registered at 4,556 K (after the impact of the IFRS 15 standard, which directly deducts distributor costs) Increased by 23.6%, supported by increased direct sales SafeOrthopedics and SafeMedical, Covid-19 pandemic limits surgical and commercial procedures Continue to do.
Annual direct sales of safe orthopedics increased by 8% thanks to German performance (+263 KE) and marketing launch in the US (+122 KE). Pool of sales and marketing staff and reduction of sales staff in France (5 in 2021, 9 in 2020) to enable investment in these last two regions and improve operating profit in Europe ) Was carried out without reducing many people in the country. coverage.

Indirect sales of safe orthopedics were 990KE, strongly influenced by Covid in the last two fiscal years of 2020 and 2021. In Japan, the Otsuka Group temporarily slowed sales of safe orthopedic products to Teijin Medical.

Safe Medical, which was fully integrated into the group in 2021, had sales of 1.8 ME, an increase of 106% from 2021 to the second half of 2020 (the company was acquired in July 2020). In parallel with this commercial acceleration, the construction of the Innovative Integrated Production Center (CIPI) will take place in Flureux-sur-Larble, and from September 2021 all industrial equipment (microbial cleaning and ready-to-use medical equipment in-house production) will be built. Room required for (white): The production transfer of the Safe Orthopedics kit has begun and all SteriSpine series will be produced in the first half of 2022.

The Group’s first financial synergies have begun to significantly increase Safe Group’s gross margin by 18%. After the transfer of SteriSpine technology in the first half of 2022, gross profit will be maximized, production time will be halved and working capital needs will be optimized.

External costs increased 23%, directly related to the Group’s return to growth, the launch of new technologies such as Hickory, Sycamore and SORA, and investment in Safe Medical, but with similar sales compared to 2019. And it decreased by 700KE. Safe Orthopedics Strengthens Clinical, Quality, and Regulatory Staff to Meet New European Requirements for “MDR” Regulations (Medical Device Regulations) and Demonstrate Sycamore’s Clinical Benefits (Clinical Performance at 3) By doing so, we have accelerated clinical investment. The month was published on December 20, 2021).

A 23% increase in labor costs will enable full-year reintegration of Safe Medical staff (compared to the five months of 2020), suspension of government financial assistance in captivity in 2020, and integrated production. Explained by hiring a clean room operator. External costs were reduced in the fourth quarter of 2021. As mentioned earlier, safe orthopedic workforce optimization has begun and correlates with commercial expectations in the direct market (FR, UK, GER, USA) to improve commercial contributions. Achieve your financial equilibrium goals within 24-36 months.

Recalling the 2019 account, we can see that the 2021 health crisis was still in full swing, but operating profit caught up with what it was before the crisis.

After a good performance of 0.87 ME due to fluctuations in the ordinary exchange rate of the subsidiary, the net performance was -6.69 ME, an improvement of 19.4% from the previous year.

“2021 was a value-creating year. We also launched new differentiated technologies such as Sycamore and SORA, accelerated sales in Germany, marketed our technology in the United States, and Safe Medical’s industrial and commercial development. Nonetheless, the COVID-19 outbreak still confused our practice, with sales increasing by 24% in 2021, but significant investment was made to build the Safe Group, and soon after innovation. Global market for technologies that can be used in the comments Safe Group Chairman and CEO Pierre Dumouchel “The 2022 road plan was communicated at the beginning of the year and can be summarized on four key axes. Digit Growth, Innovation and Digitization of Surgical Practices, Distribution to Achieve Reductions About our ecological impact and improvement of our financial performance to aim for financial balance in 3 years. 2022 is me Started in line with our plans. The United States and Germany have grown 31%, dozens of SORA and Sycamore surgeries have been performed, and 80% of our technology has been produced in-house. “

Safe recalls 2022 strategic goals

Deploy quality global distributions and accelerate double-digit growth. Our experienced sales and marketing teams are committed to facilitating the adoption of off-the-shelf products and promoting health economic benefits to hospitals, purchasing organizations, and national healthcare systems.
Sales in the United States reached 120 KE in the first quarter of 2022, compared to 129 KE for the entire 2021 (a sales representative was hired in February 2021 just in case). Sales outside the United States reached 1.3 ME in the first quarter of 2022, compared to 1.07 K in the first quarter of 2021. The new Sycamore and Hickory technologies have already boosted 30K sales while cultivating new customers at the end of the first quarter. The signing of the contract with the Clinic partner was also published during the quarter.

We will continue to innovate and digitize surgery. Launched by the SORA (Safe Operating Room Assistant) program, our team collaborates with surgeons and hospitals around the world to deploy 2.0 surgery, from first patient consultation in the operating room to postoperative clinical practice. We provide digital support up to follow-up. This data is very interesting for the design and manufacture of our technology.
Dozens of SORA-backed surgeries have already been performed at the first French evaluation center. Close collaboration with a team of surgeons has enabled us to increase the reliability of our technology, launch new features and accelerate sales by an average of 84% in two quarters. Safe Orthopedics plans to expand other units to France in the second quarter and internationally in the second half of 2022.

Reduces the impact on the ecosystem. In connection with the modernization of the SORA program and its factories, the group is working on the verification of the “green kit”. Thanks to CIPI, Safe Orthopedics is committed to reducing operating room waste by 30% and, more generally, reducing water, energy and CO2 emissions.
Since the clean room was certified in the summer of 2021, the French Safe Medical site has been certified IS013485 by AFAQ at this new industrial boundary, where 80% of Safe Orthopedics technology is produced.

Aiming for a medium-term financial balance … Despite the economic and commercial implications of COVID-19, Safe despite limiting the number of spinal surgeries performed at medical institutions around the world Group continues double-digit growth and aims for financial equilibrium within three years.
Safe held an investor meeting on April 14th to announce its progress and financial strategy. The group announced its financial results for the first half of 2022 on September 29, 2022, and has already announced a new investor conference on September 22, 2022 in Flureux-sur-Ralbul.

On the one hand, at the end of the year, it significantly refinanced to 8 ME at the level of SafeSA, subsidized from a recovery plan of up to 0.8 ME, and its balance was monetized. On the other hand, the cash of the group in March 2022 was 912KE as of December 31, 2021.